BioCentury
ARTICLE | Emerging Company Profile

Revotar: Sum of the parts

January 12, 2004 8:00 AM UTC

Only rarely does a company's restructuring produce enough spare parts to create a separate, viable company. Revotar Biopharmaceuticals AG was created in 2000 as an Encysive Pharmaceuticals Inc. subsidiary to do research on inflammation. But after a restructuring by ENCY early in 2003, Revotar gained new intellectual property that provided the capability to strike out on its own.

Revotar begins life with a Phase II inflammatory compound for multiple indications and plans to fill its pipeline by in-licensing targets and applying its expertise in inflammation, rational drug design, and preclinical and early clinical development. ...